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We conducted prospective surveillance of childhood
hemolytic uremic syndrome (HUS) from 1997 to 2001 to
describe disease incidence and clinical, epidemiologic and
microbiologic characteristics. We compared our findings,
where possible, with those of a previous study conducted
from 1985 to 1988. The average annual incidence of HUS
for the United Kingdom and Ireland (0.71/100,000) was
unchanged from 1985 to 1988. The overall early mortality
had halved, but the reduction in mortality was almost entire-
ly accounted for by improved outcome in patients with diar-
rhea-associated HUS. The principal infective cause of
diarrhea-associated HUS was Shiga toxin–producing
Escherichia coli O157 (STEC O157), although in the
1997–2001 survey STEC O157 phage type (PT) 21/28 had
replaced STEC O157 PT2 as the predominant PT. The risk
of developing diarrhea-associated HUS was significantly
higher in children infected with STEC O157 PT 2 and PT
21/28 compared with other PTs. Hypertension as a compli-
cation of HUS was greatly reduced in patients with diar-
rhea-associated HUS. 
T
he most serious manifestation of infection with Shiga
toxin–producing Escherichia coli (STEC) in humans is
hemolytic uremic syndrome (HUS). This syndrome com-
prises a triad of microangiopathic hemolytic anemia,
thrombocytopenia, and acute renal failure, usually after a
prodromal illness of acute gastroenteritis (1). At least 80%
of childhood HUS is attributable to infection with STEC
(2), mainly serogroup O157, although other serogroups are
implicated (2–10). The peak incidence of HUS is in chil-
dren <5 years of age (1). Surveillance of pediatric HUS pro-
vides valuable information on human infection with STEC.
In a prospective survey of pediatric HUS from 1985 to
1988 in the British Isles, the average annual incidence was
≈0.79 per 100,000 children <16 years of age (3). In the
intervening years, the number of laboratory-confirmed
cases of STEC O157 in England and Wales increased from
50 in 1985 (11) to 1,087 in 1997 (12). Similar increases
were seen in Scotland and Ireland (Figure). Some of the
increase in STEC O157 might reflect improved laboratory
techniques, improved detection or reporting of milder
cases, and a greater awareness of the need to investigate
diarrheal disease for STEC. If the increase in STEC O157
was real, however, then the incidence of childhood HUS
should have also increased. Therefore, we conducted
prospective surveillance of childhood HUS in the United
Kingdom and Ireland from 1997 to 2001 to describe the
impact of disease and clinical, epidemiologic, and micro-
biologic characteristics of the patients. We also compared




HUS was defined as 1) acute renal failure, including
oligoanuria and elevated creatinine level for age, 2)
microangiopathic hemolytic anemia (hemoglobin level
<10 g/L with fragmented erythrocytes), and 3) thrombocy-
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septicemia, malignant hypertension, chronic uremia, or
primary vascular disease. Diarrhea-associated HUS was
defined as disease that immediately followed diarrhea or
bloody diarrhea. Nondiarrhea-associated HUS was defined
as disease in which >1 episodes did not follow an episode
of diarrhea.
Case Ascertainment
Prospective, active surveillance of children <16 years
of age was undertaken from February 1, 1997, to January
31, 2001, in the United Kingdom and Ireland. Pediatricians
actively reported new cases of HUS in children to the
British Paediatric Surveillance Unit or the Scottish Centre
for Infection and Environmental Health, by using a card
mailed to them each month (13,14). This card allowed
them to indicate how many new cases of HUS they had
diagnosed. Physicians were also encouraged to telephone
the Public Health Laboratory Service Communicable
Disease Surveillance Centre or Scottish Centre for
Infection and Environmental Health to expedite the identi-
fication and investigation of localized outbreaks.
Clinical and Epidemiologic Data Collection
After a report was submitted to the British Paediatric
Surveillance Unit, a short, standard, structured question-
naire was mailed to the reporting clinician to collect basic
epidemiologic data that included family history, clinical
features, laboratory investigations, and initial outcome.
Outcome information was requested both on the initial
questionnaire, and if unclear, on a follow-up questionnaire
≈1 year from onset. Full renal recovery was defined as nor-
mal blood pressure and creatinine level for age and the
absence of proteinuria on strip reagent urinalysis.
Reminders were sent at the end of the study period to those
clinicians who did not return the questionnaire within a
month and to any nonresponders.
Microbiologic Investigations
Clinicians were asked to obtain fecal and serum sam-
ples from all patients with HUS (both with and without
diarrhea) according to a standard clinical protocol. Fecal
samples were examined for E. coli O157 at the local
microbiology laboratory. Presumptive E. coli O157 iso-
lates were referred to the Laboratory of Enteric Pathogens
at Colindale or the Scottish E. coli O157 Reference
Laboratory in Edinburgh (in Aberdeen until April 1999).
Fecal specimens were obtained from some patients from
whom E. coli O157 had not been isolated. Serum samples
were also referred to the reference laboratories.
Presumptive E. coli O157 isolates were confirmed bio-
chemically as E. coli and as O157 by serotyping.
Confirmed E. coli O157 isolates were phage typed and
tested for stx genes by DNA hybridization or polymerase
chain reaction (PCR). Fecal specimens referred to the ref-
erence laboratories were examined for E. coli O157 by
using immunomagnetic separation and also for all STEC
by PCR and DNAhybridization (12). Serum samples were
tested for antibodies to E. coli O157 lipopolysaccharide
(15,16). Methods for examination of isolates and fecal
samples sent to the reference laboratories from other cases
of STEC infection during the study period have been
described previously (12). 
The distribution of phage types (PTs) of STEC O157 in
patients with HUS was compared with that of all cases of
infection with STEC O157 in children <16 years of age in
England, Wales, and Scotland (comparable data for
Northern Ireland and Ireland were not available).
Data Validation and Removal of Duplicate Data
Duplicate reports for the same patient were possible
since cases might be reported both from district general
hospitals and from specialist pediatric nephrology units.
Duplicates were removed by using full name and date of
birth. Where duplicates were identified, reports from a spe-
cialist in pediatric nephrology were used in preference to
those from district general hospitals. The microbiologic
and questionnaire data were entered into a Microsoft
(Redmond, WA, USA) Access database and linked by
using full name and date of birth.
Ethical Approval 
This study was reviewed and approved by the Ethics
Committee of the Public Health Laboratory Service and
the Ethics Committee of the South Birmingham Health
Authority.
Data Analysis
Incidence rates and 95% confidence intervals (CIs)
were calculated by using population denominators
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Figure. Laboratory-confirmed infection with Shiga toxin-producing
Escherichia coli O157 in the United Kingdom, 1982–2001. Data
sources: Public Health Laboratory Service and Scottish Center for
Infection and Environmental Health. obtained from the National Statistics Office (for the United
Kingdom) and the Central Statistics Office (for Ireland).
Descriptive and statistical analyses were performed in
Microsoft Access and Excel and in STATAversion 7 (Stata
Corp., College Station, TX, USA). Differences in propor-
tions were assessed with the chi-square test, and means
were compared with the Z test.
Results
Response Rate
During the 4-year period of surveillance, 92% of pedi-
atricians responded to the active reporting system. Four
hundred thirteen cases of HUS were confirmed, of which
218 occurred in girls. Three hundred ninety-five patients
had diarrhea-associated HUS, and 18 had nondiarrhea-
associated HUS. 
Incidence
Although most of the HUS cases were reported from
England, the highest incidence rates were in Scotland
(Table 1). The average annual incidence for those <5 years
of age in Scotland was significantly higher than that in
England (risk ratio 2.28, 95% CI 1.63–2.30, p < 0.001)
(Table 1). The age and sex distributions are also shown in
Table 1.
Clinical Features and Complications
The clinical features and complications for children
from the 1997–2001 survey are summarized in Table 2
and compared with those of the HUS cases from the
1985–1988 survey (3,4). The proportions of HUS patients
with and without a diarrheal prodome were very similar in
the 2 surveys. The mean duration of illness from symptom
onset to diagnosis of HUS decreased, and smaller propor-
tions of children with diarrhea-associated HUS in the
1997–2001 survey showed severe acute abdominal symp-
toms or hypertension. HUS was reported in 20 pairs of
siblings and, in 4 instances, between cousins, with the
index patient in each incident having had a diarrheal pro-
drome.
Of the 18 children with nondiarrhea-associated HUS, 1
developed HUS during treatment for acute lymphoblastic
leukemia. The clinical course was complicated by pancre-
atitis, diabetes mellitus, and seizures. Six children had
recurrent HUS, although only 3 had recurrences during the
surveillance period. Five of these children had 1 episode of
diarrhea-associated HUS (bloody diarrhea in 3 cases).
However, all 6 children had relapses without diarrhea and
were considered cases of nondiarrhea-associated HUS. All
6 children were negative for STEC.
Treatment
Sixty-three patients with diarrhea-associated HUS
received antimicrobial agents (penicillin, metronidazole,
or a second- or third-generation cephalosporin) before
admission. Eight patients received ciprofloxacin. No sta-
tistically significant difference in outcome was seen for
those receiving antimicrobials agents (data not shown). 
Clinical Outcome
Eighty-two percent of the patients were treated in spe-
cialist pediatric nephrology centers. Outcome data were
available for 389 (98%) with diarrhea-associated HUS and
18 (100%) with nondiarrhea-associated HUS. Seven
(1.8%) children with diarrhea-associated HUS died during
acute illness compared with 14 (5.6%) of 252 (χ2 = 6.8,
p = 0.009) in the earlier survey. The early death rate for
diarrhea-associated HUS was 22% (4/18) from 1997 to
2001 compared with 21% (4/14) from 1985 to 1988 (p =
0.7, Fisher exact test). The overall early death rate for the
combined group was 2.5% compared with 5% in the
1985–1988 survey (χ2 = 6.8, p = 0.01). Eight of the 11
deaths in the 1997–2001 survey were in children <5 years
of age. In the group treated with antimicrobial agents, 3
deaths (5%) occurred compared with 4 deaths (1.2%) in
the group that was not treated. This difference was not sig-
nificant, and no significant relationship was seen when the
outcomes of death and renal impairment were analyzed
together (data not shown).
Renal recovery was reported in 342 (88%) of those with
diarrhea-associated HUS compared with 10 (56%) of those
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test). Hypertension was more likely to develop in patients
with diarrhea-associated HUS than those with nondiar-
rhea-associated HUS (p = 0.05). Seizures or other neuro-
logic complications (p = 0.008), and death (p = 0.0007)
were also more likely to occur in those with diarrhea-asso-
ciated HUS.
Microbiologic Findings for Fecal Samples and Sera
Stools and or sera were available for testing from 393
of 395 patients with diarrhea-associated HUS. Only 25
fecal samples from which presumptive E. coli O157 was
not isolated locally were examined for the presence of
STEC and non-O157 STEC by the reference laboratories.
Shiga toxin–producing E. coli O157 was confirmed in 10,
and 1 was positive for STEC O26.
The proportion of cases confirmed through fecal sam-
pling or serology was much greater (84%) than in
1985–1988, when only 31% of cases were laboratory con-
firmed (p < 0.001). In the 1997–2001 survey, 161 (60%) of
270 serum samples from patients with diarrhea-associated
HUS were positive for antibodies to E. coli O157
lipopolysaccharide. Combining results from fecal sam-
pling and serology showed that 329 (83%) of 395 patients
with diarrhea-associated HUS were infected with STEC
O157; 1 was infected with STEC O26. A total of 330
(84%) patients with diarrhea-associated HUS were infect-
ed with STEC. 
In the remaining 65 patients with diarrhea-associated
HUS, no infective agents were found in 59,
Campylobacter was found in 2, Shigella sonnei PT12 in 1,
Streptococcus pneumoniae in 1, group C Streptococcus in
1, and Staphylococcus aureus in 1. In the STEC-positive
patients, coinfections with Campylobacter (3 patients),
group B Streptococcus (1 patient), Cryptosporidium (3
patients), Salmonella (3 patients), and rotavirus (1 patient)
were identified. 
Eight patients had evidence of infection with S. pneu-
moniae, without other infections including STEC; 7 did
not have diarrhea. Two patients were girls and 6 were boys.
Three patients had hypertension, 2 showed signs of hemor-
rhage, and 4 had seizures. Five of the 8 patients made a full
renal recovery, but 1 has permanently impaired renal func-
tion, and 2 died.
Properties of STEC O157 Strains
The properties of STEC strains belonging to serogroup
O157 are summarized in Table 3. Phage typing results
were available for 220 (84%) of 261 STEC O157 isolates
from patients with diarrhea-associated HUS. The risk of
developing this type of HUS was significantly higher for
children infected with STEC O157 PT21/28 and STEC
O157 PT2.
Overall the STEC O157 PTs that predominated were
PT21/28 and PT2. However, geographic differences were
striking: PT2 was dominant in England and Wales,
PT21/28 in Scotland, and PT32 (6/10) in Ireland. Patients
in Scotland with diarrhea-associated HUS were less likely
to be infected with STEC O157 PT2 than those in England
and Wales (χ2 = 10.62, p = 0.001) but were more likely to
be infected with PT21/28 (χ2 = 14.72, p = 0.0001). In the
1985–1988 survey, PT2 was dominant (25/38, 66%) and
PT21/28 was not found.
Data on Shiga toxin typing were available for 220
strains. Most (213/220, 97%) had only stx 2 genes and 7
(3%) had stx 1 + 2 genes.
Discussion
In this survey, the average annual incidence of HUS for
the United Kingdom and Ireland from 1997 to 2001 was
unchanged from the incidence from 1985 to 1988, despite
large increases in laboratory-confirmed cases of STEC
O157 infection. This finding probably reflects underdiag-
nosis of STEC infection. Similar proportions of cases with
diarrhea-associated and nondiarrhea-associated HUS were
found, but the proportion with a confirmed diagnosis had
increased. As in the 1985–1988 survey, the principal cause
of HUS was STEC O157, but in the 1997–2001 study
STEC O157 PT21/28 had replaced STEC O157 PT2 as the
predominant PT. This finding reflected the emergence of
PT21/28 first in Scotland and subsequently in England and
Wales (17,18). However, despite the overall dominance of
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occurred across the United Kingdom and Ireland. 
The illness and death rate of patients with diarrhea-
associated HUS remained high. These children were
younger than those with nondiarrhea-associated HUS
caused by STEC and had significantly poorer outcomes.
Hypertension as a complication of HUS was greatly
reduced among patients with diarrhea-associated HUS.
The overall death rate had halved, but the reduction in
deaths was almost entirely accounted for by improved out-
comes in these cases.
The 1985–1988 and 1997–2001 surveys were similar in
most regards. Acquisition of data was identical, and the
same diagnostic criteria for HUS were used. However, a
difference in microbiologic investigation of stool samples
was seen in the 2 surveys. In the 1985–1988 survey, fresh
fecal samples were sent directly to the Public Health
Laboratory Service Division of Enteric Pathogens for cul-
turing and complete strain identification directly from clin-
ical samples. In the 1997–2001 survey, the initial
diagnostic work was undertaken in local microbiology
departments, and presumptive isolates were forwarded to
the appropriate reference laboratories for confirmation and
complete identification. The only clinical samples for-
warded to the reference laboratories were some of those
from HUS patients who were negative on examination at a
local laboratory. Although all facilities in the Public Health
Laboratory Service had been using a standard protocol
since 1995, following a recommendation of the Advisory
Committee on the Microbiological Safety of Food that all
diarrheal samples be tested for STEC O157 (11,19), this
testing was not done at all National Health Service labora-
tories. A potential criticism of this study is that non-O157
STEC strains might have been missed. This omission is
unlikely because 83% of cases had evidence of E. coli
O157 infection. Little testing for non-O157 STEC occurs
in primary diagnostic laboratories in the United Kingdom.
However, this situation needs to be balanced against the
fact that involvement of local laboratories in assisting clin-
ical investigations expedited fecal sample testing, as
shown by a marked increase in sampling, coupled with an
improved diagnostic yield. The proportion of culture-posi-
tive specimens, which was more than twice as high as in
the previous survey, was also higher than proportions
reported by other investigators (2,6,9,10). In the
1997–2001 survey, the additional benefit of serologic test-
ing for antibodies to E. coli O157 as a diagnostic tool was
evident.
Acombination of increasing diagnostic yield and short-
ening time between onset of diarrhea and diagnosis of
infection with STEC O157 should allow clinicians to mon-
itor patients and intervene earlier should signs of renal
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reduction in time to diagnosis is a function of increasing
awareness of STEC O157 infection and its complications
among clinicians and microbiologists. This finding might
explain the reduction in hypertension and deaths in
patients with diarrhea-associated HUS through earlier
intervention, including management of dehydration in
children before onset of HUS, which has been shown to
improve outcome (20). Although the reduction in neuro-
logic complications of diarrhea-associated HUS was not
significant, it might be clinically important.
STEC O157 remains the dominant cause of HUS in the
United Kingdom and Ireland, with other serotypes con-
tributing little to the overall impact of disease. This sce-
nario is similar to the situation in the United States (2), but
contrasts sharply with that in Australia, where infection
with STEC O157 is rare (7). In mainland Europe, STEC
O157 is the most common cause of HUS, but the contribu-
tion of other serotypes is also important (5,6,8–10). The
number of cases of HUS not caused by STEC O157 in the
1997–2001 survey was small and much lower than in the
previous survey. Eighty-five percent of all O157 strains
isolated from children with HUS had either of 2 PTs: PT2
and PT21/28. STEC O157 PT 21/28 emerged during this
study and was first seen in Scotland, appearing in England
and Wales 2 years later (17,18). Compared with all the
STEC O157 strains in children <16 years of age typed by
the reference laboratories, PT2 and PT21/28 strains were
overrepresented in the patients with HUS, suggesting that
these strains might have specific virulence in the children.
Most of the PT2 and PT21/28 strains produced stx2 either
alone or in combination with stx1. Shiga toxin type 2 is
generally considered an important virulence factor in the
pathogenesis of HUS (22,23).
HUS is the most important clinical effect of STEC
infection in humans, and young children are more vulnera-
ble than any other age group. It follows that surveillance of
childhood HUS is a valuable tool for monitoring the effect
of STEC in a population and provides early warning of
change. The diagnosis of HUS is obvious and unambigu-
ous, and changes in the incidence of the condition are read-
ily detected and meaningful. Moreover, by focusing on a
small indicator population, we observed that this method of
surveillance is relatively inexpensive and efficient. 
The incidence of HUS in the 1997–2001 survey was
similar to that found in 1985–1988 (3). This finding sug-
gests that the incidence of clinically relevant STEC infec-
tion has remained constant, at least in children. Therefore,
the increase in laboratory reporting over the same time
implies increased awareness and readiness to investigate
diarrhea or illness by using appropriate microbiologic
techniques. More laboratory testing and improved report-
ing might indicate that milder cases of disease are recog-
nized, so that the proportion of cases of infection with
STEC leading to HUS has decreased. Alternatively,
improving the management of diarrhea-associated HUS
through an earlier diagnosis might allow clinicians to inter-
vene earlier in the disease process, as demonstrated by
reductions in hypertension and deaths. This means that the
course of the disease might have been altered, explaining,
at least in part, the unchanged overall incidence.
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